Institute of Clinical Pharmacology, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
Acta Pharmacol Sin. 2013 Apr;34(4):555-60. doi: 10.1038/aps.2012.200. Epub 2013 Mar 18.
Cyclosporine requires close therapeutic drug monitoring because of its narrow therapeutic index and marked inter-individual pharmacokinetic variation. In this study, we investigated the associations of CYP3A4, CYP3A5, ABCB1, NFKB1, and NR1I2 polymorphisms with cyclosporine concentrations in Chinese renal transplant recipients in the early period after renal transplantation.
A total of 101 renal transplant recipients receiving cyclosporine were genotyped for CYP3A4()1G, CYP3A5()3, ABCB1 C1236T, G2677T/A, C3435T, NFKB1 -94 ins/del ATTG, and NR1I2 polymorphisms. Cyclosporine whole blood levels were measured by a fluorescence polarization immunoassay. Trough concentrations of cyclosporine were determined for days 7-18 following transplantation.
The dose-adjusted trough concentration (C0) of cyclosporine in ABCB1 2677 TT carriers was significantly higher than that in GG carriers together with GT carriers [90.4±24.5 vs 67.8±26.8 (ng/mL)/(mg/kg), P=0.001]. ABCB1 3435 TT carriers had a significantly higher dose-adjusted C0 of cyclosporine than CC carriers together with CT carriers [92.0±24.0 vs 68.4±26.5 (ng/mL)/(mg/kg), P=0.002]. Carriers of the ABCB1 1236TT-2677TT-3435TT haplotype had a considerably higher CsA C0/D than carriers of other genotypes [97.2±21.8 vs 68.7±26.9 (ng/mL)/(mg/kg), P=0.001]. Among non-carriers of the ABCB1 2677 TT and 3435 TT genotypes, patients with the NFKB1 -94 ATTG ins/ins genotype had a significantly higher dose-adjusted C0 than those with the -94 ATTG del/del genotype [75.9±32.9 vs 55.1±15.1 (ng/mL)/(mg/kg), P=0.026].
These results illustrate that the ABCB1 and NFKB1 genotypes are closely correlated with cyclosporine trough concentrations, suggesting that these SNPs are useful for determining the appropriate dose of cyclosporine.
环孢素由于其狭窄的治疗指数和明显的个体间药代动力学变异,需要密切的治疗药物监测。本研究旨在探讨 CYP3A4、CYP3A5、ABCB1、NFKB1 和 NR1I2 多态性与中国肾移植受者肾移植后早期环孢素浓度的关系。
共对 101 例接受环孢素治疗的肾移植受者进行 CYP3A4()1G、CYP3A5()3、ABCB1 C1236T、G2677T/A、C3435T、NFKB1-94ins/delATTG 和 NR1I2 多态性基因分型。采用荧光偏振免疫分析法测定环孢素全血浓度。测定移植后第 7-18 天的环孢素谷浓度。
ABCB1 2677 TT 携带者的环孢素剂量调整后谷浓度(C0)明显高于 GG 携带者和 GT 携带者[90.4±24.5 与 67.8±26.8(ng/mL)/(mg/kg),P=0.001]。ABCB1 3435 TT 携带者的环孢素剂量调整后 C0 明显高于 CC 携带者和 CT 携带者[92.0±24.0 与 68.4±26.5(ng/mL)/(mg/kg),P=0.002]。ABCB1 1236TT-2677TT-3435TT 单倍型携带者的 CsA C0/D 明显高于其他基因型携带者[97.2±21.8 与 68.7±26.9(ng/mL)/(mg/kg),P=0.001]。在 ABCB1 2677 TT 和 3435 TT 基因型非携带者中,NFKB1-94ATTGins/ins 基因型患者的环孢素剂量调整后 C0 明显高于-94 ATTGdel/del 基因型患者[75.9±32.9 与 55.1±15.1(ng/mL)/(mg/kg),P=0.026]。
这些结果表明,ABCB1 和 NFKB1 基因型与环孢素谷浓度密切相关,提示这些 SNP 可用于确定环孢素的合适剂量。